Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López, Mercedes N
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb 2009 - 945-52 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2008.18.0794 doi
Adult
Cancer Vaccines--immunology
Dendritic Cells--immunology
Disease Progression
Female
Follow-Up Studies
Humans
Hypersensitivity, Delayed--immunology
Male
Melanoma--immunology
Middle Aged
Skin Neoplasms--immunology
Survival Analysis
T-Lymphocytes, Regulatory--immunology
Transforming Growth Factor beta--biosynthesis
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb 2009 - 945-52 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2008.18.0794 doi
Adult
Cancer Vaccines--immunology
Dendritic Cells--immunology
Disease Progression
Female
Follow-Up Studies
Humans
Hypersensitivity, Delayed--immunology
Male
Melanoma--immunology
Middle Aged
Skin Neoplasms--immunology
Survival Analysis
T-Lymphocytes, Regulatory--immunology
Transforming Growth Factor beta--biosynthesis